Велферрум

Quick links to important sections

Велферрум

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Велферрум

Quick Facts

Property Description
Active Ingredient Ferric (III) Hydroxide Sacharose Complex (Iron Sucrose)
Form Sterile aqueous solution concentrate
Pharmacological Class Antianemic preparation, Parenteral Iron Replacement agent
General Purpose Correcting iron shortage and restoring iron stores
Origin Synthetic polynuclear colloidal complex

What Type of Iron Medicine is Велферрум?

Велферрум is a prescription antianemic preparation, classified as a parenteral iron replacement agent, used to address significant iron shortage in the body. This classification is recognized under the official B03AC code for parenteral iron preparations, indicating its function within the hematinic group. The medicine is defined by its single active component, Ferric (III) Hydroxide Sacharose Complex, commonly known as Iron Sucrose. This type of medicine is clinically recognized as a treatment option for patients where oral iron is ineffective, offering a distinct approach from traditional oral compounds.

Form and Origin of the Iron Sucrose Complex

The medication is supplied as a dark brown, sterile aqueous solution concentrate intended exclusively for intravenous use. This dosage form confirms its designation as a parenteral preparation. The active substance is a synthetic colloidal structure comprising a polynuclear ferric oxyhydroxide core stabilized by a protective shell of sucrose molecules. This unique complex is designed to control iron release, minimizing the amount of free iron in the blood compared to older injectable forms. This feature of controlled breakdown and release is a key distinguishing factor of Iron Sucrose.

General Purpose of the Iron Replacement Therapy

The main purpose of administering the Iron Sucrose complex is to efficiently replenish the body's total iron stores and make essential iron available for biological processes. Iron is a critical mineral required for the synthesis of hemoglobin, the protein that transports oxygen in the blood. By supplying utilizable iron directly to the circulation and storage sites (e.g., bone marrow and liver), the preparation supports the body’s ability to correct a diagnosed iron deficit, thereby counteracting the systemic effects of iron shortage, particularly when oral therapy is not suitable.

What side effects are possible with Велферрум?

Possible side effects and safety information

Official regulatory documentation structures the safety profile of Ferric (III) Hydroxide Sacharose Complex (Велферрум) by classifying possible adverse reactions according to frequency and affected body systems. These classifications are based on observed data from clinical use, distinguishing between commonly reported events and those that are rare but clinically significant.


Official Adverse Reaction Categories

Classification Examples of Documented Adverse Reactions
Common (may affect up to 1 in 10 people) Dysgeusia (taste perversion), Transient Hypotension, Nausea, and reactions at the injection site.
Uncommon (may affect up to 1 in 100 people) Hypersensitivity reactions, Headache, Dizziness, Vomiting, Abdominal pain, Urticaria (hives), Fever, and Chills.
Rare (may affect up to 1 in 1,000 people) Anaphylactoid Reactions (severe hypersensitivity), Syncope (fainting), Tachycardia (fast heart rate), and Chest pain.

Serious Adverse Reactions and Safety Constraints

The most critical adverse reactions documented in regulatory sources are Anaphylactoid Reactions (severe, potentially life-threatening allergic responses) and Severe Hypotension (significant drops in blood pressure). These events are specifically highlighted due to their clinical importance, though they are classified as Rare.

The regulatory safety profile includes restrictions on use. The medicine is generally not recommended for patients with severe hepatic impairment or in cases of non-iron deficiency anemia where iron overload is present or suspected. Specific safety notes indicate that certain effects, such as hypotension, are linked to the rate of administration, and that hypersensitivity reactions may have a delayed onset.

Overdose and Emergency Response

Overdosage with Ferric (III) Hydroxide Sacharose Complex (Велферрум) may lead to a condition defined as acute iron overloading. Regulatory documents classify the clinical outcome of persistent overload as the risk of hemosiderosis. In an overdose scenario, symptoms like hypotension or collapse may be related to the total dose delivered or the rate of administration.

The most critical risk documented by regulatory agencies is the potential for serious hypersensitivity reactions, including anaphylactic-type responses, which can escalate rapidly to shock and loss of consciousness. These severe events have been reported to be life-threatening or fatal.

When to Seek Immediate Medical Help: Treatment must be stopped immediately if any signs of intolerance or serious hypersensitivity occur during the infusion. Regulatory guidance mandates that facilities for cardiopulmonary resuscitation and the necessary personnel and therapies be immediately available for emergency intervention. Urgent medical attention is required for any manifestation of shock or loss of consciousness.

For the management of acute iron overloading, an iron chelating agent is the procedural measure specified in official documentation, if required. Patients must be observed for a minimum of 30 minutes following infusion to monitor for acute reactions. Population-specific notes indicate that severe adverse reactions in pregnant women may cause fetal bradycardia.

Therapeutic Uses of Велферрум

What Велферрум Treats: Main Uses and Benefits

This treatment is primarily applied in clinical settings marked by heightened patient distress resulting from a confirmed diagnosis of iron deficiency anemia and related iron deficiency. It is considered relevant in contexts involving heightened systemic burden where specific therapeutic criteria are met. The key therapeutic benefit is that it supports the patient during difficult episodes by easing the overall symptom burden. This class of medicine is used across domains where additional symptomatic support is needed.

The treatment is used for managing symptoms related to the underlying deficiency, addressing symptom clusters that may become intense or disruptive due to systemic imbalance. It is relevant in conditions characterized by periods of heightened symptoms, such as those associated with systemic or localized discomfort. This supportive treatment contributes to improved comfort during periods of heightened symptoms.

This medication is also relevant in acute clinical scenarios, such as when patients experience certain malabsorption disorders or blood loss requiring supportive management, where short-term symptomatic assistance is needed. This approach to supportive care helps maintain a sense of stability when symptoms are more noticeable, offering symptomatic relief that helps patients cope more steadily with challenging, energy-draining periods.

Quick Fact: Supportive care for symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

This section details the population-based eligibility and non-eligibility for Велферрум (Iron Sucrose) as defined in official regulatory labeling.

Eligibility Scope

Criteria Population Status (Official Regulatory Statement)
Use Allowed (Established) Adults and pediatric patients 2 years of age and older with Iron Deficiency Anemia (IDA) associated with Chronic Kidney Disease (CKD) [FDA]. Allowed when oral iron is unsuitable (e.g., intolerance, malabsorption) [EU SmPC].
Use Not Recommended Children younger than 2 years of age (use not established). Generally not recommended for use in children in some jurisdictions [EU SmPC].
Absolute Contraindications Must not be used in patients with evidence of iron overload or anemia not caused by iron deficiency [FDA/EU SmPC]. Contraindicated with known hypersensitivity to Iron Sucrose or other parenteral iron products [EU SmPC].

Specific Restrictions

Age/Condition Restriction or Caution
Pregnancy Contraindicated during the first trimester. Use during the second and third trimesters is restricted and permitted only if benefits clearly outweigh risks [EU SmPC].
Infection/Allergy Use with caution in patients with acute or chronic infection, a history of severe asthma or other atopic allergy. Must be stopped with ongoing bacteraemia [EU RMP].
Older Adults Dose selection requires caution, reflecting the greater frequency of age-related decreased organ function (e.g., hepatic, renal) [FDA].

Regulatory documents define use by first establishing absolute exclusions (iron status, allergy) and then restricting conditional use based on age, reproductive status, and concurrent conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ferric (III) Hydroxide Sacharose Complex (Iron Sucrose), a parenteral iron replacement medicine, is documented by regulatory authorities with specific restrictions related to co-administration and laboratory monitoring.

Interactions with Other Medicines

Co-administration with oral iron preparations is expected to result in a reduced absorption of the oral medicine. This pharmacodynamic effect is recognized in regulatory labeling for intravenous iron replacement agents, making the concurrent use of both forms counterproductive.

Interaction Type Requirement/Restriction
Physical Compatibility The medicine must not be mixed with other medicinal products or added to parenteral nutrition solutions in the intravenous bag.
Laboratory Monitoring Measurements of serum iron and Transferrin Saturation (TSAT) must be delayed by at least 48 hours following intravenous administration.

Food and Substance Interactions

Official regulatory documentation confirms there are no known interactions between the intravenous iron sucrose complex and foods or drinks. Information regarding interactions with alcohol or herbal products is not extensively documented in official prescribing information. The interaction structure is highly constrained by the medicine's intravenous delivery and its physiological role in iron regulation, rather than common metabolic pathways.

Mechanism of Action

How Велферрум Works: Mechanism of Action

Core Action: Targeted Delivery to Macrophages and RES Clearance

Велферрум (Iron(III) hydroxide sucrose complex) is a stable complex that is primarily taken up by the Reticuloendothelial System (RES) macrophages in the liver, spleen, and bone marrow via endocytosis. This key initial step of the mechanism provides a stable complex that mediates controlled release of the Ferric Iron ( Fe^3+) payload, an action that is distinct from uptake through the intestinal pathway.

Modulating the Iron Storage and Transport Pathway

Once processed by the macrophages, the released iron is immediately integrated into the body's iron cycle. It either replenishes the intracellular ferritin storage pool or binds to apotransferrin for transport throughout the body. This modulation increases the concentration of bioavailable iron for subsequent utilization.

Driving the Hemoglobin Synthesis Cascade

Sufficient transferrin-bound iron is delivered to erythroid precursor cells in the bone marrow. This iron substrate then participates in the final cascade of heme and subsequent hemoglobin synthesis, resulting in the synthesis of hemoglobin, which mediates oxygen transport.

Dosage and Administration Information

The medicine, Ferric (III) Hydroxide Sacharose Complex, is strictly designated as a parenteral iron replacement agent and is administered exclusively via the intravenous (IV) route. This administration includes a slow, undiluted injection, a diluted infusion, or directly into the venous line during a hemodialysis session. The primary dosing objective for adults is the delivery of a total cumulative dose of 1000 mg of elemental iron, which is accomplished through a specific, divided dosing regimen tailored to the patient's underlying condition.

Standard Adult Dosing Regimens

The 1000 mg total is typically divided according to the type of Chronic Kidney Disease (CKD):

Patient Population Dosing Regimen Frequency / Schedule
Hemodialysis-Dependent CKD 100 mg Per consecutive hemodialysis session
Non-Dialysis Dependent CKD 200 mg Five separate doses over a 14-day period
Peritoneal Dialysis-Dependent CKD 300 mg x 2, then 400 mg Three doses over a 28-day period

Administration Procedures and Conditions

This solution concentrate requires specific preparation: for infusion, it must be diluted only in 0.9% Sodium Chloride solution and should not be mixed with any other medications. The minimum administration time for a 100 mg infusion is 15 minutes. Standard guidelines define use for patients aged ge 2 years with specialized, weight-based maintenance doses of 0.5 mg/kg, not to exceed 100 mg per dose. The treatment course may be repeated if the underlying iron deficiency recurs.

Recent Clinical Evidence

Recent Clinical Evidence

This section reviews evidence related to the main components of the medication, primarily Iron(III)-Hydroxide Polymaltose Complex (IPC) and Folic Acid, which are commonly used together to address iron deficiency anemia (IDA).

Efficacy and Hemoglobin Levels

Research has explored the ability of oral iron complexes, such as IPC, to support the correction of IDA. In randomized controlled trials (RCTs) comparing IPC to standard ferrous salts (like ferrous sulfate) in adults with IDA, both preparations were evaluated for their effect on hemoglobin (Hb) and serum ferritin levels. One RCT involving pregnant women reported that both IPC and ferrous sulfate were associated with increases in Hb over an eight-week period, with some evidence suggesting a greater increase in the IPC group by the end of the study.

Safety and Tolerability

A key focus of research on IPC is patient compliance and gastrointestinal tolerability. Multiple clinical reviews and trials have reported that IPC is associated with a lower incidence of gastrointestinal side effects (such as nausea, vomiting, and constipation) compared to traditional ferrous salts. This difference in adverse event profiles is often linked to improved adherence to the treatment regimen.

Role of Folic Acid

Folic acid (Vitamin B9) is frequently combined with iron in supplements. Folic acid is essential for the production of red blood cells and is utilized in studies to prevent or correct folate deficiency, which can exacerbate anemia. Research confirms that supplementation supports the maintenance of adequate red blood cell levels when deficiencies are present.

Frequently Asked Questions (FAQ)

Common questions about Велферрум (FAQ)

Q: Is there a generic version of Велферрум available?

Regulatory agencies have approved generic versions of Iron Sucrose, which is the active ingredient in this medicine. Information regarding the availability of generic options is typically confirmed through a patient's pharmacy or healthcare provider.

Q: Are there different strengths of Велферрум?

Yes, Iron Sucrose Injection is typically supplied as a sterile solution containing 20 mg of elemental iron per milliliter. The medicine may be provided in vials of various total volumes to accommodate different prescribed total doses.

Q: What is the typical length of time a person takes Велферрум?

The initial treatment is typically given to administer a total cumulative dose of 1000 mg of elemental iron, which is divided into multiple doses over several weeks. The overall treatment course may need to be repeated if the patient’s iron deficiency recurs.

Q: Is Велферрум used for chronic conditions or only short-term treatment?

The medicine is approved for treating iron deficiency anemia associated with chronic kidney disease (CKD). Due to the chronic nature of CKD, treatment involves an initial correction dose that is often followed by repeated courses or maintenance doses over time.

Q: Is it necessary to finish the entire prescription of Велферрум?

The total dosage is calculated by a physician based on the patient's individual iron deficit, often with a goal of achieving a specific cumulative dose. The goal of the prescribed course is to restore the body's iron reserves, which is achieved through the administration of the calculated cumulative dose.

Q: Is there a risk of long-term problems from taking Велферрум?

Official warnings highlight the risk of excessive iron storage, known as iron overload, which can occur with cumulative or repeated therapy. This potential long-term risk is carefully managed by a healthcare provider through the periodic monitoring of the patient's iron levels with blood tests.

Q: Is Велферрум considered a high-risk medication?

The official product information includes a Boxed Warning regarding the risk of serious, potentially life-threatening hypersensitivity reactions, including anaphylaxis. Official documentation notes that the administration setting is restricted to places where trained personnel and emergency therapies are immediately available due to the risk of severe reactions.

Q: Are there specific tests required before starting Велферрум?

Yes, official guidance requires the periodic monitoring of blood parameters before starting and during treatment. These tests check important iron-related markers like hemoglobin, serum ferritin, and Transferrin Saturation ( TSAT).

Q: What clinical trials support the use of Велферрум?

Regulatory approval for the medicine is based on clinical trials conducted in patients with iron deficiency anemia and chronic kidney disease. These studies demonstrated its ability to effectively raise and maintain levels of hemoglobin and iron saturation in the body.

Q: Are there any studies looking at the long-term outcomes of Велферрум?

Studies supporting the medicine's use have been conducted, including those that specifically focus on the outcomes of repeated treatment cycles and maintenance dosing. This research is relevant for patients with chronic conditions like kidney disease.

Q: How quickly does Велферрум start working?

The iron in this intravenous product is immediately available for the body to use. However, the time it takes for you to see improvements in symptoms, like feeling less fatigued, is generally measured in weeks as the body needs time to produce new red blood cells.

Q: How long does the effect of one dose of Велферрум last?

The medicine is intended to correct the patient's total iron deficit, and the full therapeutic effect relies on the complete course of treatment, not a single injection. The benefit is maintained for a period depending on the patient's underlying condition, and repeat courses may be needed if the iron deficiency recurs.

Q: What are the signs that Велферрум is working?

The medicine works by supplying the iron needed to create hemoglobin, which improves the body's ability to transport oxygen. A physician monitors the signs of effectiveness by conducting blood tests to look for an increase in hemoglobin and ferritin levels.

Q: Is it true that Велферрум is better absorbed than other forms?

Since this medicine is administered directly into the vein, 100% of the iron dose enters the systemic circulation, meaning its availability to the body is considered 100%. This controlled delivery offers a distinct advantage over oral forms, which are subject to limited absorption in the digestive tract.

Q: Why is Велферрум sometimes prescribed over other similar drugs?

The medicine is primarily indicated for use when a patient's body cannot tolerate oral iron preparations due to issues like gastrointestinal side effects, or when the gut cannot absorb the iron effectively. Its unique intravenous administration allows for controlled iron delivery directly into the bloodstream.

Q: What is Велферрум used for, besides the main condition?

According to official product information, this medicine is approved for treating iron deficiency anemia (IDA) in adults with chronic kidney disease (CKD). It is also used for other patients who have IDA but cannot tolerate or absorb oral iron. Regulatory documents do not list other approved uses.

Q: Why do doctors recommend taking Велферрум for a long time?

Treatment aims to correct the patient's total iron deficit, which requires multiple sessions to achieve the cumulative dose needed to fully replenish body stores. Repeated courses may be necessary due to the chronic nature of the underlying conditions this medicine is used to treat.

Q: Why is consistency important when taking Велферрум?

Consistency with the schedule is important as the treatment is administered according to strict, time-sensitive dosing schedules. The treatment is designed to deliver a specific total iron dose needed to fully replenish the body's iron stores.

Q: Can Велферрум cause weight gain or loss?

Official drug labels mention peripheral edema, which is swelling or fluid retention, as a potential adverse reaction. While this can sometimes be associated with a temporary change in weight, significant weight gain or loss is not consistently listed as a common or frequent side effect.

Q: Does taking Велферрум make me feel tired?

While fatigue is a common symptom of the iron deficiency anemia being treated, it is not consistently listed as an adverse reaction in the official drug label itself. Some patients have reported temporary tiredness or weakness as side effects.

Q: Does Велферрум affect sleep or cause insomnia?

Insomnia is not listed as a common adverse reaction in official prescribing information. However, other common side effects like headache and dizziness have been reported and could potentially impact sleep.

Q: Is it safe to drive while taking Велферрум?

Official warnings state that temporary side effects like dizziness or feeling faint, which can affect alertness and coordination, may occur. Patients are advised not to drive or operate heavy machinery until they understand how the medicine affects them.

Q: Can I take Велферрум if I have high blood pressure?

High blood pressure (hypertension) is listed as an uncommon adverse reaction in clinical trials, while low blood pressure (hypotension) is a more frequent risk. Official prescribing information notes that patients with pre-existing high blood pressure should be managed with caution, as high blood pressure is listed as an uncommon adverse reaction.

Q: Is there a possibility of overdose with Велферрум?

Yes, official product information includes details about the management of an overdose. Excessive doses can cause an accumulation of iron in the body, which can be toxic and may require specific medical treatment to remove the excess iron.

Q: What should I do if my side effects from Велферрум don't go away?

Official guidelines include patient counseling information stating that all persistent symptoms should be reported to a healthcare provider. Signs of a severe or life-threatening reaction, such as breathing difficulty, severe dizziness, or chest pain, require immediate emergency medical care.

Q: Is Велферрум safe to take with common vitamins?

Official information explicitly restricts the concurrent use of this intravenous iron with oral iron preparations. The label does not specifically address non-iron vitamins. Official patient counseling states that patients should inform their healthcare provider about all concomitant vitamins and supplements.

Q: Does Велферрум interact with antacids or heartburn medicine?

Official regulatory documents do not list a specific interaction between this intravenous iron and antacids or heartburn medicines. The primary restriction is against the concurrent use of intravenous iron with oral iron preparations.

Q: What happens if I drink alcohol while using Велферрум?

Official regulatory documents do not provide extensive details on the interaction of alcohol with this intravenous iron. Caution is noted as the medicine lists dizziness as a side effect, and alcohol consumption may intensify this effect.

Q: Is Велферрум safe for pregnant or breastfeeding people?

The medicine is generally contraindicated during the first trimester of pregnancy. For the second and third trimesters, its use is restricted and permitted only if the potential benefit justifies the risk to the fetus. Official information on safety during breastfeeding is limited.

How should Велферрум be stored and disposed of?

How to Store and Dispose of Велферрум (Iron Sucrose Injection)

The official storage requirements for this sterile, parenteral solution are strictly regulated to maintain product stability.

Official Storage and Stability

Storage Requirement Rule as Documented in Labeling
Temperature Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F).
Handling Do not freeze and store in the original package. Inspect the solution to ensure it is sediment free before use.
Stability (After Opening) The medicine must be used immediately after the container is opened or after the solution is diluted.
Child Safety Keep this medicine out of the sight and reach of children.

Disposal

All unused or expired product and waste materials must be disposed of in accordance with local requirements. The medicine should not be disposed of in wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Велферрум found in:

A-Z Index: